COVID-19: economic aspects of influenza vaccine prevention

Relevance. A viral pandemic caused by the SARS-CoV-2 coronavirus has led to the development of a new coronavirus disease-2019 (COVID-19). The COVID-19 pandemic has forced the mobilization of all available health system resources. There are separate publications on reducing the risk of developing coronavirus infection in people vaccinated against influenza. Objective: to study the cost-effectiveness of influenza vaccination in the conditions of the» first « wave of COVID-19. Materials and methods. The archival data of 2,452 people from among the sick employees of JSC «Russian Railways» were analyzed. The control group consisted of 2,911 employees who were not infected with COVID-19, comparable by gender, age and territory of residence. Scores on the Charlson comorbidity scale were calculated for all individuals. The pharmacoeconomical cost of the patient’s treatment was predicted using the Markov model. Results. Having a flu shot reduced the likelihood of getting COVID-19 by 1.3 times. In the presence of a diagnosis of coronavirus infection, inpatient treatment for influenza vaccinated patients was required 2 times less often than for unvaccinated patients. Compared to the situation of the absence of vaccinated persons, in the «first wave», the estimated cost savings for the treatment of patients with coronavirus infection amounted to 124 million rubles. When the number of points on the comorbidity scale increased from 1 to 8, the average cost of treatment of patients without previous influenza vaccination increased by 2 times, and in the presence of vaccination, the average cost of treatment increased by 1.7 times. Conclusion. Thus, this study shows that influenza vaccination is cost-effective against COVID-19. The effect is achieved by reducing the likelihood of getting a coronavirus infection in the presence of a flu shot.

1. Zhu N, Zhang D, Wang W et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727-33. DOI: 10.1056/NEJMoa2001017

2. Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506. DOI: 10.1016/S0140-6736(20)30183-5

3. Schneider SM, Albert V, Barbier N et al. Adaptations de la prise en charge des patients en nutrition artifcielle à domicile au cours de l’épidémie virale COVID-19 en France: avis du Comité de nutrition à domicile de la Société Francophone de Nutrition Clinique et Métabolisme (SFNCM) Changes in care of home artifcial nutrition patients during the COVID-19 epidemics in France: position of the French-speaking Society for Clinical Nutrition and Metabolism (SFNCM)’s Home Artifcial Nutrition Committee. Nutr Clin Metab. 2020;34(2):105-7. DOI: 10.1016/j.nupar.2020.03.002

4. Ronan Thibault, Moïse Coëffier, Francisca Joly et al. How the Covid-19 epidemic is challenging our practice in clinical nutritionfeedback from the field. Eur J Clin Nutr. 2020 Sep 16;1-10. DOI: 10.1038/s41430-020-00757-6.

5. Al Rifai M, Khalid U, Misra A et al. Racial and geographic disparities in influenza vaccination in the U.S. among individuals with atherosclerotic cardiovascular disease: Renewed importance in the setting of COVID-19. Am J Prev Cardiol. 2021 Mar;5:100150. DOI: 10.1016/j.ajpc.2021.100150

6. Ali SA, Baloch M, Ahmed N et al. Te outbreak of Coronavirus Disease 2019 (COVID-19)-An emerging global health threat. J Infect Public Health. 2020;13(4):644-646. DOI: 10.1016/j.jiph.2020.02.033

7. Perkhov VI, Gridnev OV. COVID-19 pandemic lessons for policy in the feld of public health. Current problems of health care and medical statistics. 2020;(2):206-222. (In Russ).] DOI: 10.24411/2312-2935-2020-10043

8. Budarin SS. Sustainability of global health systems during the COVID-19 pandemic. Economics and management: problems, solutions. 2020;3(8):105-114. (In Russ).] DOI: 10.34684/ek.up.p.r.2020.08.03.013

9. Zhidkova EA, Gutor EM, Kalinin MR, Gurevich KG. Some aspects of delivery of health care to workers of locomotive crews in the system of the russian railway. Sistemnyi analiz i upravlenie v biomeditsinskikh sistemakh. 2018;17(2):433-439. (In Russ).]

10. Bocharova OV. Social transport institute role within a city social space. Vestnik Saratov state technical university. 2010;2(1):290-294. (In Russ).

11. Macheret DA. Razvitie transporta v kontekste sotsial’no-ekonomicheskikh problem. Transport Rossiiskoi Federatsii. 2017;71(4):16-18. (In Russ).]

12. Roshchin LV, Gol’skaya YuN. Sotsial’naya rol’ transporta v ekonomike regiona. Ekonomika regiona. 2011;(1):244-248. (In Russ).]

13. Ponomarev AA, Ieropol’skii BK. Podvizhnoi sostav i sooruzheniya gorodskogo elektrotransporta. Moscow: Transport; 1981. (In Russ).]

14. Shavrukov YuM. Razvitie gorodskogo rel’sovogo transporta. Nauka i obrazovanie. MGTU im. N.E. Baumana. Elektron. zhurn. 2014;(8):25-47. (In Russ).]

15. Gutor EM, Tkachenko YuA, Zhidkova EA, Gurevich KG. Experience of medical support for railway transport workers in the context of a new coronavirus infection. Russian Journal of Occupational Health and Industrial Ecology. 2021;61(2):125-129. (In Russ).] DOI: 10.31089/1026-9428-2021-61-2-125-129

16. Huajie Jin, Haiyin Wang, Xiao Li et al. Economic burden of COVID-19, China, January-March, 2020: a cost-of-illness study. Bull World Health Organ. 2021 Feb 1;99(2):112-124. DOI: 10.2471/BLT.20.267112

17. Molochkov AV, Karateev DE, Ogneva EYu, Zulkarnaev AB, Luchikhina EL, Makarova IV, Semenov DYu. Comorbidities and predicting the outcome of COVID-19: the treatment results of 13,585 patients hospitalized in the Moscow Region. Almanac of Clinical Medicine. 2020;48(S1):S1—10. (In Russ).] DOI: 10.18786/2072-0505-2020-48-040.